Cost of anaesthetic drugs and clinical budgeting J R LETHBRIDGE, J SECKER WALKER
In 1980 Astley and Secker Walker calculated that the average total cost to the National Health Service of one anaesthetic was £29-98. ' The cost of drugs for the year 1979-80 was £44 032 or 8 6% of the total hospital cost of anaesthesia of £506 459. This paper examines the drugs bill for the University College Hospital group of hospitals between April 1984 and March 1985 and compares it directly with the study of the drugs bill for 1979-80.' It highlights the financial consequences of changes in anaesthetic practice. We have also examined the cost of anaesthesia for one hour in 1985 and compared it with the cost of anaesthesia for the same operation (hysterectomy) lasting one hour in 1980. This shows how the choice of the newer anaesthetic drugs in 1985 led to a rise in costs, when compared with 1980, which is above the percentage rise of the Retail Price Index. Medical and nursing staff salaries account for 83% of the cost of anaesthesia, but the cost of anaesthetic drugs is the next most important factor. If the drugs bill were allowed to rise faster than the annual increase for inflation in the departmental budget it would be necessary to make equivalent economies elsewhere in the anaesthetic department's budget. Tables I-III show popularity. By 1985 the use of thiopentone had increased to the point where it accounted for 95% of the total money spent on induction agents; the corresponding figure for 1980 was 76%.
Cost of drugs and equipment
The new muscle relaxants atracurium and vecuronium are considerably more expensive than the older drugs such as pancuronium and tubocurarine, whose prices have decreased in real terms. Other new drugs that have been added to the armamentarium of anaesthetists, such as glycopyrronium and doxapram, have also made a contribution to the increased drugs bill.
We examined the costs of drugs and disposable equipment that are commonly used in anaesthesia for hysterectomy and compared them with those same costs as reported for 1980. Three important points emerge.
The cost of the disposable items commonly used by the anaesthetist during a hysterectomy have decreased.
The cost of the one hour anaesthetic using the older muscle relaxant pancuronium and the older volatile agent halothane has decreased in real terms.
When the newer drugs are used-vecuronium instead of pancuromum and enflurane instead of halothane-there is a substantial real increase in the drug component of the anaesthetic cost from £2 99 to £5-09. This is a real increase of £2-10 or 70%; it represents the price to be paid for using the newer anaesthetic drugs after making allowances for inflation. The new drugs such as enflurane and vecuronium, however, tend to be more expensive than the older drugs with which they are competing. Furthermore, the introduction of the new muscle relaxants vecuronium and atracurium may be encouraging anaesthetists to ventilate patients who previously were being allowed to breathe spontaneously. The shorter duration ofaction of these newer muscle relaxants may allow anaesthetists to ventilate patients for short procedures when previously this was less practicable. Although the price of enflurane has come down since 1980, it remains nearly three times the cost of halothane, the drug that it commonly replaces, and it is six times the cost for one MAC hour.* The present government insists that district health authorities remain within their cash limits, and similar rules will apply to departmental budgets. Clinical budgeting in the anaesthetic departmente was described before the Griffiths management changes. 5 The inquiry insisted that clinical budgets should be introduced more widely as a means of maintaining tighter financial control and responsibility. A review of clinical budgeting and costing experiments noted how clinical costing did not usually, in itself, encourage clinicians to change their pattern of expenditure,' but the same review reported a more encouraging picture emerging from clinical budgeting, with the active participation of clinicians trying to keep within agreed expenditure plans.
The effect ofchanges in anaesthetic practice brought about partly by the introduction of new drugs may be compounding the effect of the increased costs of the drugs themselves. The increased use of more expensive drugs is a factor that may lead to problems in departmental budgeting, as it will become necessary to make corresponding savings elsewhere in the departmental budget. The need to search elsewhere within the budget to balance the overspending on pharmacy will inevitably lead the budget holder to consult among his colleagues with questions, perhaps uncomfortable, about costs of anaesthetic equipment, costs of various anaesthetic techniques, maintenance costs, study leave, staffing levels, and so on. Ifthe budget holder and his colleagues are certain that no further savings can be made within the department then it will be necessary to approach the unit manager for additional funding. It will be necessary to defend the need to use new drugs that cost more than the Department of Health and Social Security has allowed for inflation. It is possible that additional funds could be provided only by making savings in other specialty budgets, and this could give rise to discussions, for example, about the relative benefit to patients of expensive staple guns for anastomoses versus newer relaxant drugs. If there is a failure to make this case in many districts faced with the same financial problems this could seriously inhibit the development of new techniques in anaesthesia.
As computer terminals are installed in operating theatre offices, as doubtless they will be, there will be easier access to measurements of anaesthetic caseload against which the pharmacy bill will have to be balanced. The University College Hospital anaesthetic department's budget does not include the cost of drugs at present, but there are plans for this to be changed once computers are able to collect all the necessary data. 4 In this way a form of medical audit is bound to begin. It is probably better that clinicians undertake this audit themselves rather than have it imposed on them by the new management structure.
The data presented here have shown those factors that are tending to increase the drugs bill faster than the rate ofrise ofthe Retail Price Index. These factors include the changing practices ofanaesthetists and the increasing use of new and umore expensive drugs, which are steadily replacing some of the older favourites. A recent editorial in the BMJ noted that in the United States halothane has almost completely been supplanted by enflurane and isoflurane and made the point that health authorities should pay for the more expensive agent rather than have to join the medical insurers in paying large *Minimu alveolar concentration (MAC). This refers to the alveolar concentration at which half the subjects will not respond to a surgical stimulus. Because enflurane has a MAC of l-7% and halothane has a MAC of 0 7% more enflurane than halothane is used when the drugs are used in equivalent concentrations. This leads to enflurane costing six times as much as halothane when used to produce anaestei of equivalent depth. settlements for avoidable halothane hepatitis.7 Although the data presented here show that the higher cost ofnewer drugs is one ofthe main factors in the increasing drugs bill, with many of the older drugs becoming relatively cheaper, there is one notable exception. Since the collection ofthe data for this paper the cost ofthiopentone 500 mg with water has risen from £133 (including VAT) in July 1985 to £l-66 in May 1986. This is a price rise of 22-5% during a period when the Retail Price Index rose by less than 5%. As this study shows that thiopentone is a major component of the total drugs bill it is easy to see how a large increase in price of such an important item could have serious sequelae elsewhere within the anaesthetic department's budget. Both the increased use ofthis well established drug and its increasing price could be because there are now fewer competing induction agents than there were in 1980. We have contacted the makers ofthiopentone, who tell us that the rise in price is related to substantial increases in manufacturing costs as the manufacture of thiopentone is a complicated and labour intensive process.
The present study illustrates that in the context of clinical budgeting a budget for anaesthetic drugs, uplifted annually for inflation and sensitive to changes in workload, would nevertheless have caused serious problems for the budget holder.
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